Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: villar lm. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.
Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis.
Domínguez-Mozo MI, Casanova I, Monreal E, Costa-Frossard L, Sainz-de-la-Maza S, Sainz-Amo R, Aladro-Benito Y, Lopez-Ruiz P, De-Torres L, Abellán S, Garcia-Martinez MA, De-la-Cuesta D, Lourido D, Torrado-Carvajal A, Gomez-Barbosa C, Linares-Villavicencio C, Villar LM, López-De-Silanes C, Arroyo R, Alvarez-Lafuente R. Domínguez-Mozo MI, et al. Among authors: villar lm. Int J Mol Sci. 2024 Sep 17;25(18):10012. doi: 10.3390/ijms251810012. Int J Mol Sci. 2024. PMID: 39337499 Free PMC article.
COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.
Sainz de la Maza S, Rodero-Romero A, Monreal E, Chico-García JL, Villarrubia N, Rodríguez-Jorge F, Fernández-Velasco JI, Sainz-Amo R, Costa-Frossard L, Masjuan J, Villar LM. Sainz de la Maza S, et al. Among authors: villar lm. Front Immunol. 2024 Aug 22;15:1439393. doi: 10.3389/fimmu.2024.1439393. eCollection 2024. Front Immunol. 2024. PMID: 39238642 Free PMC article.
Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
Sainz-Amo R, Rodero Romero A, Monreal E, Chico García JL, Fernández Velasco JI, Villarrubia N, Veiga González JL, Sainz de la Maza S, Rodríguez Jorge F, Masjuan J, Costa-Frossard L, Villar LM. Sainz-Amo R, et al. Among authors: villar lm. Front Immunol. 2024 Aug 19;15:1454474. doi: 10.3389/fimmu.2024.1454474. eCollection 2024. Front Immunol. 2024. PMID: 39224593 Free PMC article.
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J, Cubas-Núñez L, Piqueras M, Castillo-Villalba J, Quintanilla-Bordàs C, Quiroga-Varela A, Villarrubia N, Monreal E, Álvarez G, Gasque-Rubio R, Forés-Toribio L, Carratalà-Boscà S, Lucas C, Sanz MT, Ramió-Torrentà L, Villar LM, Casanova B, Laiz B, Pérez-Miralles FC. Tortosa-Carreres J, et al. Among authors: villar lm. J Neuroimmunol. 2024 Sep 15;394:578428. doi: 10.1016/j.jneuroim.2024.578428. Epub 2024 Aug 3. J Neuroimmunol. 2024. PMID: 39121816
Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults.
Rodero-Romero A, Monreal E, Sainz-Amo R, García Domínguez JM, Villarrubia N, Veiga-González JL, Fernández-Velasco JI, Goicochea-Briceño H, Rodríguez-Jorge F, Sainz de la Maza S, Chico-García JL, Muriel A, Masjuan J, Costa-Frossard L, Villar LM. Rodero-Romero A, et al. Among authors: villar lm. Int J Mol Sci. 2024 Jul 17;25(14):7808. doi: 10.3390/ijms25147808. Int J Mol Sci. 2024. PMID: 39063050 Free PMC article.
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD, Hegen H, Villar LM, Rejdak K, Sao-Aviles A, Carbonell-Mirabent P, Sastre-Garriga J, Mongay-Ochoa N, Berek K, Martínez-Yélamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke JN, Rosenstein I, Alvarez-Lafuente R, Castillo-Trivino T, Otaegui D, Llufriu S, Blanco Y, Sánchez López AJ, Garcia Merino JA, Fissolo N, Gutierrez L, Villacieros-Álvarez J, Monreal E, Valls-Carbó A, Wiendl H, Montalban X, Comabella M. Lunemann JD, et al. Among authors: villar lm. Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200270. doi: 10.1212/NXI.0000000000200270. Epub 2024 Jun 21. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38912898 Free PMC article.
A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R. Dominguez-Mozo MI, et al. Among authors: villar lm. Front Immunol. 2024 Jun 7;15:1384411. doi: 10.3389/fimmu.2024.1384411. eCollection 2024. Front Immunol. 2024. PMID: 38911861 Free PMC article.
68 results